Capsule Formulation and Quality Testing

A capsule looks simple: a shell, a powder and a cap. Behind each one sits a series of formulation and manufacturing decisions, and a set of tests that show whether every unit in a batch contains what the label states. Capsule content uniformity is the most important of those tests, because a batch whose average content is correct can still contain individual units that sit well above or below target. Disintegration and dissolution testing, together with identity and assay, complete the core picture.

This article describes how capsule research material is formulated and filled, then explains the pharmacopeial concepts behind the main quality tests, drawing on USP general chapters <905>, <701> and <711> and their harmonized counterparts. It closes with what a capsule certificate of analysis should report.

Capsule Types

Hard two-piece capsules are the format most relevant to powder-filled research material. A body and a cap telescope together, and shells come in standard sizes numbered from 000, the largest, down to 5, the smallest. Gelatin, derived from collagen, is the traditional shell material. It dissolves readily in warm aqueous media and has a long manufacturing history, but it holds a substantial amount of water in equilibrium with its surroundings and can cross-link when exposed to heat, humidity or reactive impurities such as aldehydes, which slows dissolution.

Hydroxypropyl methylcellulose (HPMC) shells are the main alternative. They contain less water and are less prone to cross-linking, which suits moisture-sensitive or aldehyde-sensitive contents, though some HPMC grades made with gelling agents show dissolution behavior that depends on the ionic composition of the medium. Soft capsules, which enclose liquids or suspensions in a one-piece shell, are a separate technology with their own methods. In research supply, capsules remain a minority format; most research peptides online, ours included, are supplied as lyophilized powder or liquid in vials, so the tests below matter mainly when a capsule format is being evaluated.

Fill and Blend

Most capsule fills are blends rather than pure active material. Diluents such as microcrystalline cellulose, lactose or starch bring the fill to a weight that the capsule size and filling equipment can handle accurately. Glidants such as colloidal silicon dioxide improve powder flow, and lubricants such as magnesium stearate reduce sticking to equipment. Lubricant level deserves care, since magnesium stearate is hydrophobic and excessive amounts or over-mixing can slow wetting and dissolution.

Uniformity begins with the blend. If the active material is not evenly distributed, no amount of filling precision will produce uniform capsules. The risk is greatest when the active fraction is small, when particle sizes of active and excipients differ widely, or when a well-mixed blend segregates during transfer. Manufacturers manage this with geometric dilution, controlled particle size, validated mixing times and blend uniformity sampling before filling. At production scale, filling is done by dosator or tamping-disc machines; at small scale, by manual or semi-automatic plates, with weight checks throughout the run.

Content Uniformity

Uniformity of dosage units is defined in USP <905>, harmonized with the European Pharmacopoeia (2.9.40) and the Japanese Pharmacopoeia. It can be demonstrated in one of two ways. Content uniformity assays the active ingredient in each of a set of individual units. Weight variation instead weighs individual units and calculates each unit’s content from the assay of a composite sample, which assumes the blend is homogeneous. For hard capsules, the chapter permits weight variation only when the active ingredient is present at 25 mg or more and makes up at least 25% of the unit by weight; otherwise content uniformity is required.

The harmonized test does more than check that each unit falls inside a percentage window. It calculates an acceptance value (AV) that combines the deviation of the sample mean from the reference value with the spread of individual results. In the first stage, ten units are tested and the AV must not exceed a limit L1, which is 15.0 unless otherwise specified. If that stage fails, twenty more units are tested; the AV for all thirty must then meet L1, and no individual unit may deviate from the reference value by more than a second limit, L2, usually 25.0%. Because the AV penalizes both a biased mean and a wide spread, a batch can fail even when its average content is exactly on target.

For peptide-containing capsules, the hardest part is often the assay itself. The method, usually reversed-phase HPLC, must extract the peptide quantitatively from the excipient matrix and resolve it from excipient peaks and degradants, and it should be validated for that purpose following ICH Q2(R2). This is the same principle behind our lot-level quality testing: results are only as trustworthy as the validated method that produced them, applied here to individual units rather than a bulk sample.

Disintegration and Dissolution Testing

A capsule that holds the right amount of material is only useful if that material is released predictably. Disintegration testing under USP <701> places units in a basket-rack assembly that moves up and down in a liquid medium held at 37 °C and records whether they break apart within a specified time. It is a coarse measure, but quick and useful for routine release.

Dissolution testing under USP <711> is more informative. It measures how much active material dissolves into a defined medium over time, usually with the basket apparatus (Apparatus 1) or the paddle apparatus (Apparatus 2). Capsules tend to float in the paddle apparatus, so a sinker, typically a small wire helix, keeps them submerged. Samples are withdrawn at set times and assayed, and results are compared with an acceptance criterion expressed as Q, the specified amount dissolved at a stated time. Gelatin cross-linking is a recognized cause of slowing dissolution on storage, and pharmacopeial practice allows a second tier of testing with enzymes such as pepsin or pancreatin added to the medium to distinguish cross-linking from a genuine formulation problem. For peptide fills, the method must also account for the peptide’s own stability and adsorption in the dissolution vessel, or a degradation artifact may be mistaken for incomplete release.

Identity, Assay and What a Capsule COA Reports

A certificate of analysis for capsule material should report each of the following with the method used and the acceptance criterion alongside the result:

• Identity of the active ingredient, for a peptide typically by mass spectrometry and HPLC retention time against a reference.
• Assay, the mean content per capsule as a percentage of label claim.
• Uniformity of dosage units, stating whether content uniformity or weight variation was used and giving the acceptance value.
• Dissolution or disintegration, with the medium, apparatus and time point.
• Related substances, reporting degradants and impurities.
• Water content and, where relevant, microbial limits.

A lot number, test date and the name of the testing laboratory make the certificate traceable, and ICH Q6A sets out the general framework for which tests belong in a specification for a solid unit form. When reading any certificate, check that the tests match the format: a COA reporting only HPLC purity of a bulk powder says nothing about whether individual capsules are uniform. Our overview of peptide purity testing explains how lot data are generated and reported, and the guide on how to read a peptide COA covers the analytical basics. For a comparison of capsules with other formats, see lyophilized vs liquid peptides.

Why Unit-Level Testing Matters

Capsule quality is a property of individual units, not just of a batch average. Blend homogeneity, accurate filling, a shell suited to its contents and a validated assay together determine whether each capsule holds what it should and releases it as expected. The pharmacopeial tests for uniformity, disintegration and dissolution exist to make that demonstrable. For researchers, the practical lesson is to look for unit-level data on any capsule certificate and to treat its absence as missing information.

References

1. United States Pharmacopeia. General Chapter <905> Uniformity of Dosage Units.
2. United States Pharmacopeia. General Chapter <711> Dissolution.
3. United States Pharmacopeia. General Chapter <701> Disintegration.
4. European Pharmacopoeia. Chapter 2.9.40 Uniformity of Dosage Units.
5. International Council for Harmonisation. ICH Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.
6. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.